Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 190 Lung Neoplasms 67 Ovarian Neoplasms 64 Breast Neoplasms 38 Fallopian Tube Neoplasms 33 Small Cell Lung Carcinoma 31 Parkinson Disease 4, Autosomal Dominant Lewy Body 27 Carcinoma, Ovarian Epithelial 24 Uterine Cervical Neoplasms 22 Triple Negative Breast Neoplasms 22 Squamous Cell Carcinoma of Head and Neck 19 Neuroblastoma 17 Carcinoma 17 Adenocarcinoma of Lung 17 Neoplasm Metastasis 15 Endometrial Neoplasms 14 Neoplasms 12 Head and Neck Neoplasms 11 Recurrence 8 Peritoneal Neoplasms 8 Carcinoma, Transitional Cell 8 Esophageal Neoplasms 7 Central Nervous System Neoplasms 7 Brenner Tumor 7 Urinary Bladder Neoplasms 6 Lung Diseases 6 Adenocarcinoma, Bronchiolo-Alveolar 6 Thoracic Neoplasms 5 Testicular Neoplasms 5 Respiratory Tract Neoplasms 5

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Vitamin D 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma, Cutaneous Malignant × Carboplatin × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡